{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:41:55Z","timestamp":1790710915691,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104568","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:53:38Z","timestamp":1756277618000},"page":"104568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+\/HER-2 breast cancer patients treated with CDK4\/6 inhibitors"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-0291","authenticated-orcid":false,"given":"Omar","family":"Badran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Darawshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sireen","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih","family":"Yosef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.104568_bib1","volume":"1","year":"2016","journal-title":"Breast cancer screening Lyon (FR): International Agency for Research on Cancer"},{"issue":"6","key":"10.1016\/j.breast.2025.104568_bib2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/jso.27459","article-title":"Oncologic anthropology: global variations in breast cancer risk, biology, and outcome","volume":"128","author":"Newman","year":"2023","journal-title":"J Surg Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib3","doi-asserted-by":"crossref","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.breast.2025.104568_bib4","series-title":"Breast cancer [Internet]","article-title":"Subtypes of breast cancer","author":"Orrantia-Borunda","year":"2022"},{"issue":"10","key":"10.1016\/j.breast.2025.104568_bib5","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","article-title":"Palbociclib in combination with fulvestrant in women with hormone Receptor-Positive\/HER2-Negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3)","volume":"21","author":"Verma","year":"2016","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.breast.2025.104568_bib6","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104568_bib7","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.breast.2025.104568_bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.seminoncol.2018.01.006","article-title":"Mechanisms of therapeutic CDK4\/6 inhibition in breast cancer","volume":"44","author":"Scott","year":"2017","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/curroncol32010052","article-title":"Real-world experience with CDK4\/6 inhibitors in the first-line palliative setting for HR+\/HER2\u2212 advanced breast cancer","volume":"32","author":"Patel","year":"2025","journal-title":"Curr Oncol"},{"issue":"17","key":"10.1016\/j.breast.2025.104568_bib10","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.3390\/ijms21176400","article-title":"Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"34","key":"10.1016\/j.breast.2025.104568_bib11","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104568_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.breast.2025.104568_bib13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0142","article-title":"Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4\/6 inhibitors in breast cancer: practical considerations and recommendations","volume":"22","author":"Spring","year":"2017","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.breast.2025.104568_bib14","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","article-title":"Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies","volume":"22","author":"Hu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.104568_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918793326","article-title":"Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer","volume":"10","author":"Thill","year":"2018","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.breast.2025.104568_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/jcm14041071","article-title":"Evaluation of dose reduction factors and impact on progression-free survival in patients treated with CDK 4\/6 inhibitors","volume":"14","author":"G\u00fcren","year":"2025","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.breast.2025.104568_bib17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1080\/0284186X.2020.1804613","article-title":"Efficacy and safety of cyclin-dependent kinases 4\/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience","volume":"59","author":"Edman Kessler","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.breast.2025.104568_bib18","article-title":"Could a simple biomarker such as a neutrophil-to-lymphocyte ratio, reflect complex processes orchestrated by neutrophils?","volume":"6","author":"Kourilovitch","year":"2022","journal-title":"J Transl Autoimmun"},{"issue":"12","key":"10.1016\/j.breast.2025.104568_bib19","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.18240\/ijo.2019.12.18","article-title":"Neutrophil-to-lymphocyte ratio in ocular diseases: a systematic review","volume":"12","author":"Kurtul","year":"2019","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/03007995.2023.2174327","article-title":"Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio, and platelet-lymphocyte ratio in stroke-associated pneumonia: a systematic review and meta-analysis","volume":"39","author":"Zawiah","year":"2023","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.1016\/j.breast.2025.104568_bib21","doi-asserted-by":"crossref","first-page":"32171","DOI":"10.18632\/oncotarget.16291","article-title":"Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis","volume":"8","author":"Bowen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2025.104568_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2021.11.021","article-title":"Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer","volume":"163","author":"Bryant","year":"2022","journal-title":"Lung Cancer"},{"issue":"20","key":"10.1016\/j.breast.2025.104568_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033811","article-title":"Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: a retrospective observational cohort study","volume":"102","author":"Jadoon","year":"2023","journal-title":"Medicine (Baltim)"},{"issue":"6","key":"10.1016\/j.breast.2025.104568_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4048\/jbc.2022.25.e44","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio and early standardized uptake value reduction in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"25","author":"Bae","year":"2022","journal-title":"J Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104568_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21037\/atm-22-5612","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study","volume":"11","author":"Yan","year":"2023","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.breast.2025.104568_bib26","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.3389\/fonc.2020.01752","article-title":"Elevated neutrophil-to-lymphocyte ratio is associated with poor outcomes for melanoma patients treated with PD-1 inhibitor or chemotherapy in a Chinese population","volume":"10","author":"Qi","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.breast.2025.104568_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/hepr.12019","article-title":"Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma","volume":"43","author":"Limaye","year":"2013","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.breast.2025.104568_bib28","first-page":"25","article-title":"Prognostic role of baseline neutrophil-to-lymphocyte ratio in metastatic solid tumors","volume":"13","author":"Zucker","year":"2020","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib29","article-title":"Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions","volume":"10","author":"Gago-Dominguez","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.breast.2025.104568_bib30","doi-asserted-by":"crossref","first-page":"e675","DOI":"10.1016\/j.clbc.2020.05.008","article-title":"Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis","volume":"20","author":"Cullinane","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104568_bib31","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers12040958","article-title":"Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review","volume":"12","author":"Corbeau","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.breast.2025.104568_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4048\/jbc.2021.24.e43","article-title":"Neutrophil to lymphocyte ratio after treatment completion as a potential predictor of survival in patients with triple-negative breast cancer","volume":"24","author":"Kim","year":"2021","journal-title":"J Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2025.104568_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-018-05106-7","article-title":"Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer","volume":"174","author":"Patel","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53606-3","article-title":"Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables","volume":"9","author":"Ivars Rubio","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.breast.2025.104568_bib35","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.21873\/invivo.12970","article-title":"Neutrophil-lymphocyte ratio is associated with occurrence of febrile neutropenia in patients treated with 5-Fluorouracil and cisplatin","volume":"36","author":"Kumazawa","year":"2022","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31557\/apjcb.2020.5.3.81-87","article-title":"Pretreatment absolute neutrophil-to-lymphocyte ratio (NLR) predict the risk for febrile neutropenia in the first cycle adjuvant chemotherapy for breast cancer","volume":"5","author":"Chantharakhit","year":"2020","journal-title":"Asian Pacific Journal of Cancer Biology"},{"key":"10.1016\/j.breast.2025.104568_bib37","unstructured":"Chaichana Chantharakhit, N. S. (n.d.). Pretreatment absolute neutrophil-to-lymphocyte ratio (NLR) predict the risk for febrile neutropenia in the first cycle adjuvant chemotherapy for breast cancer."},{"key":"10.1016\/j.breast.2025.104568_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/20420986241278498","article-title":"Adverse event profiles of CDK4\/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system","volume":"15","author":"Shen","year":"2024","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","article-title":"CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis","volume":"21","author":"Onesti","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","article-title":"Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice","volume":"150","author":"Sibaud","year":"2023","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.breast.2025.104568_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1247270","volume":"13","author":"Cazzaniga","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.104568_bib42","unstructured":"Clalit Research Institute. (n.d.). https:\/\/www.clalit-innovation.org\/clalitresearchinstitute."},{"key":"10.1016\/j.breast.2025.104568_bib43","series-title":"Membership in sick funds 2016","article-title":"National insurance institute of Israel","author":"Cohen","year":"2017"},{"issue":"7","key":"10.1016\/j.breast.2025.104568_bib44","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/jcm14072509","article-title":"Neutrophil-to-Lymphocyte ratio as a prognostic biomarker for long-term survival in older adults at a mental health care center: a historical cohort analysis","volume":"14","author":"Chmielewski","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.breast.2025.104568_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2023.104598","article-title":"Neutrophil-to-lymphocyte ratio an inflammatory biomarker, and prognostic marker in heart failure, cardiovascular disease and chronic inflammatory diseases: new insights for a potential predictor of anti-cytokine therapy responsiveness","volume":"150","author":"Garc\u00eda-Escobar","year":"2023","journal-title":"Microvasc Res"},{"issue":"6","key":"10.1016\/j.breast.2025.104568_bib46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.pan.2016.09.007","article-title":"The combination of systemic inflammation-based marker NLR and circulating regulatory T cells predicts the prognosis of resectable pancreatic cancer patients","volume":"16","author":"Cheng","year":"2016","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.breast.2025.104568_bib47","first-page":"75","article-title":"Zahorec index or neutrophil-to-lymphocyte ratio, valid biomarker of inflammation and immune response to infection, cancer and surgery","volume":"125","author":"Firment","year":"2024","journal-title":"Bratisl Lek Listy"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2009.11.002","article-title":"Lymphocytes in cancer development: polarization towards pro-tumor immunity","volume":"21","author":"Ruffell","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.breast.2025.104568_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2024.104215","article-title":"Forged in the fire: lasting impacts of inflammation on hematopoietic progenitors","volume":"134","author":"Cao","year":"2024","journal-title":"Exp Hematol"},{"issue":"7","key":"10.1016\/j.breast.2025.104568_bib50","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201545","article-title":"Inflammatory signaling regulates hematopoietic stem and progenitor cell development and homeostasis","volume":"218","author":"Collins","year":"2021","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib51","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40425-018-0383-1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.breast.2025.104568_bib52","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.21037\/tcr-20-3237","article-title":"Neutrophil-to-lymphocyte ratio predicts prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"10","author":"Lin","year":"2021","journal-title":"Transl Cancer Res"},{"issue":"12","key":"10.1016\/j.breast.2025.104568_bib53","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/biom13121803","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) in NSCLC, gastrointestinal, and other solid tumors: immunotherapy and beyond","volume":"13","author":"Mosca","year":"2023","journal-title":"Biomolecules"},{"issue":"18","key":"10.1016\/j.breast.2025.104568_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015369","article-title":"A meta-analysis of the impact of neutrophil-to-lymphocyte ratio on treatment outcomes after radiotherapy for solid tumors","volume":"98","author":"Choi","year":"2019","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.breast.2025.104568_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1228076","article-title":"The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers: a narrative review","volume":"13","author":"Heshmat-Ghahdarijani","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.104568_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100347","article-title":"Unveiling the link between chronic inflammation and cancer","volume":"25","author":"Tripathi","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.breast.2025.104568_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exphem.2023.09.002","article-title":"Chronic inflammation promotes cancer progression as a second hit","volume":"128","author":"Burocziova","year":"2023","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.breast.2025.104568_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann Afr Med"},{"issue":"1","key":"10.1016\/j.breast.2025.104568_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.breast.2025.104568_bib61","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2025.104568_bib62","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2- ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.breast.2025.104568_bib63","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.3390\/cancers15143658","article-title":"On behalf of the eadv task force dermatology for cancer patients. cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV task force \"Dermatology for Cancer Patients\" international study","volume":"15","author":"Sollena","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:10:19Z","timestamp":1762344619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"alternative-id":["S0960977625005855"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104568","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+\/HER-2 breast cancer patients treated with CDK4\/6 inhibitors","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104568"}}